Apimeds Pharmaceuticals US I
13F holders, Q2 2025 (June 30)6holders
1famous investor
$1.76avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Apimeds Pharmaceuticals US I in their 13F filings. The largest holders were Yorkville Advisors Global, LP ($440K), Citadel Advisors ($24K) and Goldman Sachs Group Inc. ($21K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Apimeds Pharmaceuticals US I
- CUSIP
- 03771D102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $50K |
| Exits | 0 | $0 |
Ownership 6 holders
| Yorkville Advisors Global, LP | 0.13% | — | 250,000 | $440K |
| Citadel Advisors | 0.00% | New | 13,359 | $24K |
| Goldman Sachs Group Inc. | 0.00% | New | 11,987 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,151 | $6K |
| Bank of America Corp. | 0.00% | New | 29 | $52 |
| JPMorgan Chase & Co. | 0.00% | New | 5 | $9 |
"% of holder's portfolio" is APIMEDS PHARMACEUTICALS US I's weight in each manager's 13F, not the share of Apimeds Pharmaceuticals US I the manager owns.